SEARCH:   Advanced

Blood, 22 January 2009, Vol. 113, No. 4, pp. 793-796. Prepublished online as a Blood First Edition Paper on October 17, 2008; DOI 10.1182/blood-2008-07-172080. This Article Full Text (PDF) Supplemental Appendix All Versions of this Article: blood-2008-07-172080v1 113/4/793    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Dhodapkar, M. V Articles by Barlogie, B. Search for Related Content PubMed PubMed Citation Articles by Dhodapkar, M. V Articles by Barlogie, B. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted July 30, 2008 Accepted September 27, 2008 Long term survival in Waldenstrom Macroglobulinemia - 10 year follow-up of Southwest Oncology Group (SWOG) directed intergroup trial S9003 Madhav V Dhodapkar*, Antje Hoering, Morie A Gertz, Saul Rivkin, Jackie Szymonifka, John Crowley, and Bart Barlogie Section of Hematology and Yale Cancer Center, Yale University, New Haven, CT, United States Cancer Research and Biostatistics, Seattle, WA, United States Mayo Clinic, Rochester, MN, United States Puget Sound Oncology Consortium, Seattle, WA, United States Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, United States * Corresponding author; email: madhav.dhodapkar{at}yale.edu. Survival of patients with Waldenstrom Macroglobulinemia (WM) varies enormously. Development of prognostic models in WM has been fraught by limited follow up in current studies. Here we update the outcome of a prospective WM trial with a median follow up of 10 years for live patients. Of the 59 previously untreated patients who were initially observed, 12 patients (21%) required therapy at a median follow up of 100 months. Multivariate analysis among the 183 patients requiring therapy reaffirmed age >=70yr, prior non-protocol therapy and beta-2-microglobulin (B2M) >=3mg/dL as prognostic factors. Importantly, elevated serum lactate dehydrogenase (LDH) was identified as an additional independent variable, which improved risk assessment beyond the recent WM-international prognostic scoring system (ISSWM). Using age, prior therapy, B2M and LDH, we identified 3 risk groups with 8-year survival estimates of 55%, 33% and 5% (p<0.0001). These data provide novel insights into factors predicting long-term outcome in WM. This trial has been registered with www.cancer.gov under ID 4852904. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: S. P. Treon How I treat Waldenstrom macroglobulinemia Blood, September 17, 2009; 114(12): 2375 - 2385. [Abstract] [Full Text] [PDF]

	Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020